Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

74.75
BATS BZX Real-Time Price
As of 2:56pm ET
 +0.56 / +0.75%
Today’s Change
66.93
Today|||52-Week Range
83.58
+2.62%
Year-to-Date
Novartis' Acute Heart Failure Drug Fails in Late-Stage Study
Mar 22 / Zacks.com - Paid Partner Content
Conatus Pharma (CNAT) Incurs Wider-than-Expected Loss in Q4
Mar 16 / Zacks.com - Paid Partner Content
Array BioPharma's NDA for Cancer Drug Withdrawn; Shares Down
Mar 22 / Zacks.com - Paid Partner Content
Glaxo Files for Label Expansion of Influenza Vaccine in US
Mar 16 / Zacks.com - Paid Partner Content
Novartis Shares Extend Declines After Serelaxin Fails Global Phase III Trials
Mar 22 / TheStreet.com - Paid Partner Content
Novartis Takes Aim at Pfizer in Breast Cancer
Mar 14 / MotleyFool.com - Paid Partner Content
Security Asset Management Buys TransDigm Group, Intel, Novartis AG, Sells Cerner, Tim...
Mar 21 / GuruFocus News - Paid Partner Content
Novartis Breast Cancer Drug OK'd by FDA as First-line Therapy
Mar 14 / Zacks.com - Paid Partner Content
Does Novartis (NVS) Stock Make a Good Value Pick?
Mar 21 / Zacks.com - Paid Partner Content
Aerie Resubmits Rhopressa NDA, Roclatan Gains Traction
Mar 13 / Zacks.com - Paid Partner Content
6 Reasons to Invest in GlaxoSmithKline (GSK) Stock in 2017
Mar 21 / Zacks.com - Paid Partner Content
How Incyte Stock Became a Bull Market Star for Biotech Investors
Mar 10 / Zacks.com - Paid Partner Content
Lilly's Breast Cancer Combo Drug Phase III Results Positive
Mar 21 / Zacks.com - Paid Partner Content
5 Reasons Celgene Will Be a Top Biotech Stock for the Next Decade
Mar 09 / MotleyFool.com - Paid Partner Content
Novartis (NVS) Announces Positive Data on Heart Failure Drug
Mar 20 / Zacks.com - Paid Partner Content